High serum alanine aminotransferase levels for the first three successive years can predict very high incidence of hepatocellular carcinoma in patients with Child Stage A HCV-associated liver cirrhosis

Scandinavian Journal of Gastroenterology

Volumn 44, Issue 11, 2009, Pages 1340-1348

  Miyakawa, Kaoru ^a,b   Tarao, Kazuo ^b   Ohshige, Kenji ^c   Morinaga, Soichiro ^a   Ohkawa, Shinichi ^a   Okamoto, Naoyuki ^a   Shibuya, Akitaka ^d   Adachi, Shigeru ^d   Miura, Yukiko ^d   Fujiyama, Shigetoshi ^e   Miyase, Shiho ^e   Tomita, Kimio ^f  

^a KANAGAWA CANCER CENTER   (Japan)

^b Tarao's Gastroenterological Clinic   (Japan)

^c YOKOHAMA CITY UNIVERSITY   (Japan)

^d KITASATO UNIVERSITY   (Japan)

^e NTT West Kyushu Hospital   (Japan)

^f KUMAMOTO UNIVERSITY   (Japan)

Author keywords

Hepatitis C virus associated liver cirrhosis; Hepatocellular carcinoma; Incidence of hepatocellular carcinoma; Risk of hepatocellular carcinoma; Serum alanine aminotransferase

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ANTIINFLAMMATORY AGENT; ASPARTATE AMINOTRANSFERASE;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER INCIDENCE; CONTROLLED STUDY; CORRELATIONAL STUDY; FEMALE; FOLLOW UP; HEPATITIS C VIRUS; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROTHROMBIN TIME; RETROSPECTIVE STUDY; THROMBOCYTE COUNT;

ALANINE TRANSAMINASE; CARCINOMA, HEPATOCELLULAR; DISEASE PROGRESSION; DNA, VIRAL; FEMALE; FOLLOW-UP STUDIES; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INCIDENCE; JAPAN; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; POLYMERASE CHAIN REACTION; PROGNOSIS; RETROSPECTIVE STUDIES; TIME FACTORS;

EID: 70449513975     PISSN: 00365521     EISSN: 15027708     Source Type: Journal    
DOI: 10.3109/00365520903222681     Document Type: Article

References (40)

1. Slaga TJ, Scribner JD. Inhibition of tumor initiation and promotion by anti-inflammatory agents. J Natl Cancer Inst 1973;51:1723-1725
2. Cameron R, Lee G, Farber E. Chemical mitogens as effective alternatives to partial hepatectomy in the new model for the sequential analysis of hepatocarcinogenesis. Proc Am Assoc Cancer Res 1978;19:56.
3. Marks F, Bertsch S, Grimm W, Schweizer J. Hyperplastic transformation and tumor promotion in mouse epidermis: possible consequences of disturbances of endogenous mechanism controlling proliferation and differentiation. In: Slaga TJ, Sivak A, Boutwell RK, editors. Carcinogenesis, vol.2. New York: Raven Press; 1978. pp 97-116.
4. Argyris TS. Tumor promotion by damage-induced epidermal hyperplasia in the skin of mice. Proc Am Assoc Cancer Res 1979;20:4.
5. Vasiliev JM, Moizhess TG. Tumorigenicity of sarcoma cells is enhanced by the local environment of implanted foreign body. Int J Cancer 1982;30:525-529
6. Hamada J, Takeichi N, Okuda F, Ren J, Li X, Hosokawa M, et al. Progression of weakly malignant clone cells derived from rat mammary carcinoma by host cells reactive to plastic plates. Jpn J Cancer Res 1992;83:483-490
7. Nomura A, Stemmermann GN, Chyou PH, Kato I, Perez- Perez GI, Blaser MJ. Helicobacter pylori infection and gastric carcinoma among Japanese Americans in Hawaii. N Engl J Med 1991;325:1170-1171
8. Uemura N, Okamoto S, Yamamoto S, Matsumura N, Yamaguchi S, Yamakido M, et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 2001;345:784-789
9. Lennard-Jones JE, Melville DM, Morson BC, Ritchie JK, Williams CB. Precancer and cancer in extensive ulcerative colitis: findings among 401 patients over 22 years. Gut 1990;31:800-806
10. Belamaric J. Intrahepatic bile duct carcinoma and C. sinensis infection in Hong Kong. Cancer 1973;31:468-473
11. Sugihara S, Kojiro M. Pathology of cholangiocarcinoma. In: Okuda K, Ishak KG, editors. Neoplasms of the Liver. Tokyo: Springer; 1987. pp 143-158
12. Shiratori Y, Imazeki F, Moriyama M, Yano M, Arakawa Y, Yokosuka O, et al. Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann Intern Med 2000;132:517-524
13. Okita M, Sakaida I, Hino K. Current strategies for chemoprevention of hepatocellular carcinoma. Oncology 2002; 62Suppl:24-28
14. Tarao K, Rino Y, Ohkawa S, Shimizu A, Tamai S, Miyakawa K, et al. Association between high serum alanine aminotransferase levels and more rapid development and higher rate of incidence of hepatocellular carcinoma in patients with hepatitis C virus-associated cirrhosis. Cancer 1999;86:589-595
15. Child CG III, Turcotte JG. Surgery and portal hypertension. Dunphy JE, editor. The liver and portal hypertension. Philadelphia: WB Saunders; 1964. p 50.
16. Gratzner HG. Monoclonal antibody to 5-bromo- and 5-iododeoxyuridine: a new reagent for detection of DNA replication. Science 1982;218:474-476
17. Tarao K, Ohkawa S, Shimizu A, Harada M, Nakamura Y, Ito Y, et al. Significance of hepatocellular proliferation in the development of hepatocellular carcinoma from antihepatitis C virus-positive cirrhotic patients. Cancer 1994;73: 1149-1154
18. Tarao K, Shimizu A, Ohkawa S, Tamai S. Prediction of the development of hepatocellular carcinoma from HCV-associated liver cirrhosis. J Jpn Soc Int Med 1995;84:1985-1991
19. Yumoto Y, Jinno K, Tokuyama K, Araki Y, Ishimitsu T, Maeda H, et al. Hepatocellular carcinoma detected by iodized oil. Radiology 1985;154:10-24.
20. Suzuki H, Ohta Y, Takino T, Fujisawa K, Hirayama C. Effects of glycyrrhizin on biochemical tests in patients with chronic hepatitis double blind trial. Asian Med J 1983;26:423-438
21. Hirayama C, Okumura M, Tanikawa K, Yano M, Mizuta M, Ogawa N. A multicenter randomized control clinical trial of Sho-saiko-to in chronic active hepatitis. Gastroenterol Jpn 1989;24:715-719
22. Hino K, Miyakawa H, Takahashi J, Kumada H, Ikeda K, Yoshida A, et al. Histological improvement in inflammation in chronic hepatitis by administration of stronger-seominophargen C (SNMC) [in Japanese]. Kan-Tan-Sui 1986;13:797-807.
23. Bellentani S, Podda M, Tiribelli C, Callea F, Marazzi M, Sodde M, et al. Ursodiol in the long-term treatment of chronic hepatitis: a double-blind multicenter clinical trial. J Hepatol 1993;19:459-464
24. Tarao K, Tamai S, Ohkawa S, Miyakawa K, Aoki H, Takashimizu S, et al. The effects of combined drug therapy on the serum alanine aminotransferase level in HCV-associated liver cirrhosis [in Japanese]. Rinsho-to Kenkyu 1998;75:1858-1867.
25. Hosmer DW, Lemeshow S. Applied logistic regression. Chichester, UK: John Wiley; 1989.
26. Gooley TA, Leisenring W, Cyowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks; new presentation of old estimations. Stat Med 1999;18: 695-706.
27. Kaplan EL, Meier P. Nonparametric estimation for incomplete observation. J Am Stat Assoc 1958;53:457-481
28. Mahmood S, Togawa K, Kawanaka M, Niiyama G, Yamada G. An analysis of risk factors for developing hepatocellular carcinoma in a group of hepatitis C patients with stage 3 fibrosis following interferon therapy. Cancer Inform 2008;6:381-387
29. Oka H, Tamori A, Kuroki T, Kobayashi M, Yamamoto S. Prospective study of alpha-fetoprotein in cirrhotic patients monitored for development of hepatocellular carcinoma. Hepatology 1994;19:61-66
30. Ishiguro S, Inoue M, Tanaka Y, Mizokami M, Iwasaki M, Tsugane S, et al. Serum aminotransferase level and the risk of hepatocellular carcinoma: a population-based cohort study in Japan. Eur J Cancer Prev 2009;18:26-32.
31. Kurokawa M, Hiramatsu N, Oze T, Mochizuki K, Yakushiji T, Kurashige N, et al. Effect of interferon alpha- 2b plus ribavirin therapy on incidence of hepatocellular carcinoma in patients with chronic hepatitis. Hepatol Res 2009;39:432-438
32. Kumada T, Toyoda H, Kiriyama S, Sone Y, Tanikawa M, Kanamori A, et al. Incidence of hepatocellular carcinoma in hepatitis C carriers with normal alanine aminotransferase levels. J Hepatol 2009;50:729-735
33. Kumada T, Toyoda H, Kiriyama S, Sone Y, Tanikawa M, Hisanaga Y, et al. Long-term follow-up of patients with hepatitis C with a normal alanine aminotransferase. J Med Virol 2009;81:446-451
34. Ferenc S, Bela M, Tamas Z, Lajos B, Zsolt T. Growth in epithelial cell proliferation and apoptosis correlates specifically to the inflammation activity of inflammatory bowel diseases: ulcerative colitis shows specific p53- and EGFR expression alterations. Dis Col Rect 2005;48:775-786
35. Kasai H, Nishimura S. Hydroxylation of deoxyguanosine at the C-8 position by ascorbic acid and other reducing agents. Nucleic Acid Res 1984;12:2137-2145
36. Shibutani S, Takeshita M, Grollman AP. Insertion of specific bases during DNA synthesis past the oxidation-damaged base 8-oxodG. Nature (Lond) 1991;349:431-434
37. Shiota G, Maeta Y, Mukoyama T, Yanagidani A, Udagawa A, Oyama K, et al. Effect of sho-saiko-to on hepatocarcinogenesis and 8-hydroxy 2¢ deoxyguanosine formation. Hepatology 2002;35:1125-1133
38. Nakae D, Kobayashi Y, Akai H, Andoh N, Satoh H, Ohashi K, et al. Involvement of 8-hydroxyguanosine formation in the initiation of rat liver carcinogenesis by low dose levels of N-nitrosodiethylamine. Cancer Res 1997;57:1281-1287
39. Shimoda R, Nagashima M, Sakamoto M, Yamaguchi N, Hirohashi S, Yokota J, et al. Increased formation of oxidative DNA damage, 8-hydroxydeoxyguanosine, in human livers with chronic hepatitis. Cancer Res 1994;54:3171-3172
40. Ikeda K, Saitoh S, Arase Y, Chayama K, Suzuki Y, Kobayashi M, et al. Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: a long-term observation study of 1,643 patients using statistical bias correction with proportional hazard analysis. Hepatology 1999;29:1124-1130